ClinicalTrials.gg
RecruitingNCT07181824PAVM-RéaCHSFUpdated Dec 9, 2025

VAP Incidence and Adequation to SRLF 2017 Diagnostic Among an Intensive Care Medicine Service for the Period 2022 à 2024

An observational study in Pneumonia Ventilator Associated, sponsored by Centre Hospitalier Sud Francilien. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by Centre Hospitalier Sud Francilien · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 80 studies in Pneumonia, Ventilator-Associated with a site in France — 20 open to participants now, 22 under way, 3 of them phase 3. Pneumonia, Ventilator-Associated · France.

Planned enrollment
21st of 33
100 · median 268
Started
2025
with 4 others
Observational
33 of 80
9 open now
Primary completion
2026-06
later than 7 of 21 live
Registered
74th of 80
by date
Lead sponsor
2 of 80
Centre Hospitalier Sud Francilien

Among the 80 studies in Pneumonia, Ventilator-Associated with a site in France, this one is the 21st largest by planned enrollment of the 33 observational ones that give a count, is one of 5 that started in 2025, is one of 33 observational ones, reaches primary completion later than 7 of the 21 other live ones, and was the 74th registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

20 of the 80 studies in Pneumonia, Ventilator-Associated with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Pneumonia, Ventilator-Associated with a site in France, or all of them as a file.
02

Study summary

The goal of this observational study is to to analyze respiratory samples performed in mechanically ventilated ICU patients and to assess whether the SRLF criteria for defining VAP were respected among patients admited to the Intensive care medicine at a regional hospital en France

Read the detailed description

Ventilator-associated pneumonia (VAP) is a lung infection that occurs after more than 48 hours of mechanical ventilation. It is of particular interest because it affects between 5-40% of ICU patients depending on the study and diagnostic criteria, with a relatively low attributable mortality (around 10%), but with increased morbidity, notably in terms of the duration of mechanical ventilation and ICU length of stay. In addition, it is the leading cause of nosocomial infection in the ICU, accounting for up to 25% of antibiotic use for hospital-acquired infections.

The diagnosis of VAP is based on clinico-radiological criteria: the appearance or worsening of a radiological pulmonary infiltrate, an inflammatory syndrome, the appearance of secretions, increased oxygen dependency and/or worsening of shock, confirmed by a positive respiratory sample.

The diagnostic challenge lies in the fact that the signs and symptoms are not pathognomonic of VAP and may be common to other conditions. On the other hand, patients may be colonized by pathogens without actually having VAP.

For this reason, scientific societies propose criteria to better target patients for whom a respiratory sample should be taken and antibiotic therapy initiated.

In 2017, the French Society of Intensive Care Medicine (SRLF) and the French Society of Anaesthesia and Intensive Care (SFAR) published recommendations on ICU-associated pneumonia, with some minor variations compared with the 2005 ATS/IDSA criteria.

Our study aims to analyze respiratory samples performed in mechanically ventilated ICU patients and to assess whether the SRLF criteria for defining VAP were respected.

03

Conditions studied

  • Pneumonia Ventilator Associated

Keywords

  • Ventilatory associated pneumonia
  • VAP
  • Intensive Care medicine
  • Mechanical ventilation
  • Pneumonia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Population includes all patients admitted to the intensive care unit for the selected period, under mechanical ventilation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 18 years
  • Hospitalization in Intensive care unit for the period between 01/01/2022 and 31/12/2024
  • Intubation and mechanical ventilation for > 48h
  • Positive respiratory sample

Exclusion criteria

Exclusion Criteria:

  • Decision of therapeutic limitation
  • Organ donors
  • Patient refuse to participate
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • VAP suspicion

    Adult patients (\>18 years) under mechanical ventilation for \>48 hours and with a positive respiratory sample

    Other: Diagnostic tedst

Interventions

  • OtherDiagnostic tedst

    * Radiologic signs: 2 consecutive thorax x-ray with new onset pneumonia AND * One of the following criteria * Fever \>38,3°C without any other cause * Leucocytes \< 4000/mm3 or ≥ 12000 /mm3 * AND at least two of the following * Purulent secretions * Cough or dyspnoea * Desaturation or increase in FiO2 (+20%)

06

What researchers measure

Primary outcomes

  1. SRLF VAP criteria

    Describe whether the respiratory samples obtained from ICU patients after \>48 hours of mechanical ventilation for suspected VAP met, or did not meet, the 2017 SRLF diagnostic criteria

    Time frame: at day 0

Secondary outcomes

  1. microbial ecology in the ICU of CHSF

    Prevalence of MDR in the respiratory samples

    Time frame: at day 0

  2. antibiotic consumption generated by VAP

    To evaluate antibiotic consuming related to VAP episodes to the total antibiotic consuming in the Intensive care unit

    Time frame: at day 0

  3. morbidity and mortality associated with VAP

    Mortality and mechanical ventilation duration among patients diagnosed of VAP

    Time frame: at day 0

  4. duration of antibiotic therapy for a VAP episode

    Duration of antibiotherapy among patients with VAP

    Time frame: at day 0

  5. characteristics of the initial antibiotic therapy

    Number and class of antibiotics of the initial antibiotic therapy

    Time frame: at day 0

  6. Evaluate the adequacy of the initial antibiotic therapy

    Adequation of the initial therapy compared to the definitive therapy: maintain, increase or reduce the spectrum or number of antibiotics

    Time frame: at day 0

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Jun 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2025
First posted
Sep 18, 2025
StartActual
Aug 25, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07181824
Lead sponsor
Centre Hospitalier Sud Francilien
Responsible party
Sponsor
First posted
Sep 18, 2025
Start date
Aug 25, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Dec 9, 2025

Study contacts

Luis ENSENYAT MARTIN, MD
Contact
luis.ensenyatmartin@chsf.fr
33 1 61 69 31 57 ext. +33
Caroline TOURTE
Contact
caroline.tourte@chsf.fr
33 1 61 69 31 50 ext. +33
Luis ENSENYAT MARTIN, MD
principal investigator · Centre Hospitalier Sud Francilien
Abdoul DINE
study director · Centre Hospitalier Sud Francilien

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion